Browse News
Filter News
Found 17,724 articles
-
BiomX Announces the Appointment of Susan Blum to its Board of Directors
4/18/2024
BiomX Inc. today announced the appointment of Susan Blum to its Board of Directors.
-
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
4/18/2024
TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 Antibody indications for patients with relapsing forms of multiple sclerosis (RMS).
-
NeoGenomics Announces Senior Leadership Promotions
4/18/2024
NeoGenomics, Inc. today announced two promotions within its senior leadership team, effective immediately.
-
Castellum, Inc. Announces New Strategic Alliance
4/18/2024
Castellum, Inc. announces a new strategic alliance between its subsidiary Specialty Systems, Inc. (“SSI”) (www.specialtysystems.com ) and Epic Systems, Inc. (“Epic”) (www.epicinfotech.com ).
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Point Of Care Diagnostics Market Size to Increase USD 80.75 Bn by 2033
4/17/2024
According to Nova One Advisor, the global point of care diagnostics market size was accounted for USD 44.25 billion in 2023 and it will increase to around USD 80.75 billion by 2033 with a CAGR of 6.2% from 2024 to 2033.
-
Bionano and Diagens Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis that Combines OGM and Artificial Intelligence
4/17/2024
Bionano Genomics, Inc. (BNGO), a global leader in the transformation of the cytogenetic workflow with OGM, today announced that it has entered into an original equipment manufacturing (OEM) partnership agreement with Diagens, an assisted reproductive technology company based in China focused on the application of AI in cytogenetics.
-
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
4/17/2024
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
-
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
4/17/2024
BioLineRx Ltd. today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma.
-
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
4/16/2024
Innovent Biologics, Inc. announces the appointment of Dr. Nageatte Ibrahim, a world-famous Oncology Clinical Development Leader in the Pharmaceutical Industry, as the Oncology CMO.
-
Oncology Market Size to Exceed USD 521.60 Billion by 2033 | CAGR 8.9%
4/16/2024
The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024
-
Diagnostic Testing Market Size to Reach USD 449.78 Billion by 2033
4/16/2024
According to Nova One Advisor, the global diagnostic testing market is valued at USD 211.27 billion in 2023
-
Agricultural Biotechnology Market is Projected to Achieve Sustainable Growth 8.6%
4/16/2024
According to Precedence Research, the global agricultural biotechnology market was evaluated at USD 115.26 billion in 2023
-
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
4/16/2024
Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
-
VBI Vaccines Reports Full Year 2023 Financial Results
4/16/2024
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced financial results for the year ended December 31, 2023.
-
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
4/16/2024
Amneal Launches PEMRYDI RTU ® , the First Ready-to-Use Version of Important Oncology Injectable Medicine.
-
U.S. Biopharmaceutical CMO & CRO Market Size, Share & Growth Report, 2033
4/15/2024
The U.S. biopharmaceutical CMO & CRO market size was estimated at USD 10.82 billion in 2023 and is projected to hit around USD 19.75 billion by 2033, growing at a CAGR of 6.2% during the forecast period from 2024 to 2033.
-
Structural Biology Market Experiencing Rapid Growth
4/15/2024
The global structural biology market is expanding rapidly worldwide, and between 2023 and 2032, hundreds of millions of dollars are expected to be generated in revenue altogether.
-
Syntec Optics (Nasdaq: OPTX) Announces Executive Changes to Support Growth Plan
4/15/2024
Syntec Optics Holdings, Inc. announced today executive-level changes.
-
Outset Medical Partners with American Nephrology Nurses Association to Support Nephrology Nursing and Patient Care
4/15/2024
Outset Medical, Inc. today announced its partnership with the American Nephrology Nurses Association (ANNA) as a member of its new Partnership Advisory Council.